China
Africa
Explore chapters and articles related to this topic
Dictionary
Published in Mario P. Iturralde, Dictionary and Handbook of Nuclear Medicine and Clinical Imaging, 1990
Radiobinding assay. A general method of analysis in which the concentration of a ligand (L) is measured by allowing L and a fixed amount of a similar radiolabeled ligand (L*) to react with a given amount of receptor reagent (R), resulting in a distribution of L* into two separable compartments (bound and unbound). The distribution of L*, which varies as function of the total concentration of a ligand (L + L*) present, is estimated by the magnitude that the dilution L exerts on the label in the bound or free compartment or on some function of bound and free.
Autoantibodies in Pandemrix®-induced narcolepsy: Nine candidate autoantigens fail the conformational autoantibody test
Published in Autoimmunity, 2019
Madeleine Wallenius, Alexander Lind, Omar Akel, Emma Karlsson, Markus Svensson, Elin Arvidsson, Anita Ramelius, Carina Törn, Lars Palm, Åke Lernmark, Helena Elding Larsson
The current study could not associate NT1 to autoantibodies against TRIB2, POMC/α-MSH, DP1, KIR4.1 or ANO2. TRIB2 is the only NT1-associated autoantigen for which the results from the initial study have been re-confirmed by other authors [17–19]. Studies suggesting TRIB2 as an autoantigen for NT1 have been able to detect autoantibody positivity among 16–26% of studied narcolepsy cases, proposing the autoantigen to be present in a subgroup of patients. Results in the current study were consistent with previous reports from our lab which could not demonstrated increased levels of TRIB2 autoantibodies among patients with Pandemrix®-induced narcolepsy [20]. It is recognized for many autoimmune diseases, including type 1 diabetes [38], Graves’ disease, Hashimoto’s thyroiditis and Addison’s disease [39,40], that autoantibodies predominately detect conformational epitopes. The advantage of the current study is the use of in vitro transcription translation for expression of proteins together with radiobinding assay which enable detection of such conformational dependent autoantibodies [46]. A possible limitation with the use of RBA is the consideration of post-translational modifications (PTMs), mechanisms linked to autoimmunity [47].
Protocol for a nested case-control study design for omics investigations in the Environmental Determinants of Islet Autoimmunity cohort
Published in Annals of Medicine, 2023
Helena Oakey, Lynne C. Giles, Rebecca L. Thomson, Kim-Anh Lê Cao, Pat Ashwood, James D. Brown, Emma J. Knight, Simon C. Barry, Maria E. Craig, Peter G. Colman, Elizabeth A. Davis, Emma E. Hamilton-Williams, Leonard C. Harrison, Aveni Haynes, Ki Wook Kim, Kylie-Ann Mallitt, Kelly McGorm, Grant Morahan, William D. Rawlinson, Richard O. Sinnott, Georgia Soldatos, John M. Wentworth, Jennifer J. Couper, Megan A. S. Penno
Autoantibodies to IAA were measured by a radiobinding assay. Prior to October 2017, autoantibodies to GAD, IA2 and ZnT8 were measured by immunoprecipitation of 35S-methionine-labelled recombinant human proteins. From October 2017, autoantibodies to GAD, IA2 and ZnT8 were initially assayed by the ELISA RSR 3-screen ICA kit; samples exceeding the positive threshold were re-tested in separate ELISA RSR kits for autoantibodies to GAD, IA2 and ZnT8.